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Dominant-negative ATF5 rapidly depletes survivin
in tumor cells
Xiaotian Sun1, James M. Angelastro2, David Merino1,3, Qing Zhou1, Markus D. Siegelin1 and Lloyd A. Greene1
Abstract
Survivin (BIRC5, product of the BIRC5 gene) is highly expressed in many tumor types and has been widely identified as
a potential target for cancer therapy. However, effective anti-survivin drugs remain to be developed. Here we report
that both vector-delivered and cell-penetrating dominant-negative (dn) forms of the transcription factor ATF5 that
promote selective death of cancer cells in vitro and in vivo cause survivin depletion in tumor cell lines of varying
origins. dn-ATF5 decreases levels of both survivin mRNA and protein. The depletion of survivin protein appears to be
driven at least in part by enhanced proteasomal turnover and depletion of the deubiquitinase USP9X. Survivin loss is
rapid and precedes the onset of cell death triggered by dn-ATF5. Although survivin downregulation is sufficient to
drive tumor cell death, survivin over-expression does not rescue cancer cells from dn-ATF5-promoted apoptosis. This
indicates that dn-ATF5 kills malignant cells by multiple mechanisms that include, but are not limited to, survivin
depletion. Cell-penetrating forms of dn-ATF5 are currently being developed for potential therapeutic use and the
present findings suggest that they may pose an advantage over treatments that target only survivin.
Introduction
The transcription factor ATF5 is over-expressed in a
variety of cancer types and such over-expression corre-
lates with poor prognosis and treatment resistance1–18.
ATF5 is a member of the activating transcription factor
family and possesses a basic leucine zipper domain that is
required for association with selected partners as well as
DNA binding and transcriptional activity2–4,19–22. To
interfere with ATF5 function, we developed a dominant-
negative (dn) form of this protein that retains the native
leucine zipper, but is N-terminally truncated and modified
in the basic domain to abolish DNA binding and to
potentially extend the leucine zipper23. When expressed
in tumor cells in vitro or in vivo, dn-ATF5 promotes their
apoptotic death and causes tumor regression2–4,9,10,13,24.
To generate a dn-ATF5 with therapeutic potential, we
designed a form fused to a cell-penetrating “penetratin”25
domain that can be produced either as a recombinant
protein26 or by synthesis27. The presence of the cell-
penetrating domain permits the penetratin-dn-ATF5
fusion peptide (CP-dn-ATF5) to rapidly pass through
tissue barriers and to enter cells26. Both recombinant and
synthetic forms of CP-dn-ATF5 effectively promote
apoptosis of a wide variety of tumor cells in vitro and
in vivo26,27. In contrast, neither plasmid nor penetratin
delivered dn-ATF5 appears to affect survival of non-
transformed cells and there have been no evident side-
effects in mice treated with either the recombinant or
synthetic forms of CP-dn-ATF5 at doses that suppress
tumor growth2,24,26,27.
The mechanisms by which dn-ATF5 promotes tumor
cell death are only partially understood. dn-ATF5
decreases levels of anti-apoptotic proteins BCL2 and
MCL1 in tumor cells by what appears to be both
decreased transcription and elevated protein destabiliza-
tion5,27,28. A preliminary survey of additional proteins that
regulate cell survival and death indicated that dn-ATF5
may also affect expression of the inhibitor-of-apoptosis
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protein (IAP) family member survivin (BIRC5, product of
the BIRC5 gene). Like ATF5, survivin is highly expressed
in multiple tumor types with little expression in most
non-transformed cells29. High survivin expression in
tumors is correlated with metastasis, resistance to treat-
ment and poor prognosis30,31. In addition to its action as
an inhibitor of apoptosis, biological roles for survivin that
also appear to contribute to its actions in tumors include
regulation of cell cycle and promotion of mitochondrial
function31. Agents that directly or indirectly down-
regulate survivin levels interfere with the proliferation of
cancer cells and promote their apoptotic death and thus,
given survivin’s absence from most non-transformed cells,
it has been widely considered as an attractive potential
target for cancer treatment30–36. Consequently, there has
been substantial effort to identify/generate agents that
suppress survivin expression in neoplasias31,33–36. To
date, no such drug has reached clinical use beyond trials,
neither as a mono- or combination therapy. Thus there is
a continued need to identify agents that affect survivin
expression and that have the potential to be used as safe
cancer therapeutics.
Materials and methods
Cells culture and transfection
GBM12 cells were kindly supplied by Dr. Jann Sarkaria
(Mayo Clinic). All other cell lines were obtained from the
ATCC and authenticated by the supplier. All lines were
grown in DMEM supplemented with 10% fetal bovine
serum, 100 U/ml penicillin and 100 U/ml streptomycin.
siUSP9X (#6308 S, Cell Signaling Technology, Danvers
MA), siSurvivin (#6351, Cell Signaling Technology;
(#4390824, Silencer Select S1458, Ambion), siRNA CTR
(#6568, Cell Signaling Technology; SilencerTM Select
Negative Control, #4390843, Ambion) were transfected
into cells using Oligofectamine™ Transfection Reagent
(Invitrogen, Waltham MA) following the supplier’s proto-
cols. All plasmids were transfected by using Lipofectamine™
3000 (Invitrogen) following the supplier’s protocols.
Plasmids
FLAG-tagged human survivin cDNA cloned into a
pCMV6-entry vector was obtained from Origene, Rock-
ville MD (#RC205935). The plasmid used for FLAG-
survivin over-expression was pLVX-EF1α-IRES-mCherry
(#631987, Takara Bio USA, Mountainview CA), a bicis-
tronic lentiviviral vector allowing the expression of the
transgene and mCherry under the control of the EF1-α
promoter. FLAG-survivin was generated and cloned in
the pLVX vector using primers AAGAATTC (EcoRI)
ATGGGTGCCCCGACGTTG and AATCTAGA(XbaI)
TTACTTATCGTCGTCATC. GFP-BCL237 was a gift
from Clark Distelhorst (Addgene plasmid # 17999; http://
n2t.net/addgene:17999; RRID:Addgene_17999).
Indicated experiments employed wild-type and mutant
pCMV-1A-3xFLAG-dn-ATF5. To generate these con-
structs, DNA optimized for human codon usage with a 5’-
BamHI site and a 3’-XhoI site were synthesized as gBlock
fragments (Integrated DNA Technologies Inc, Skokie IL)
encoding the wild-type dn-ATF5 sequence, MASMTGG
QQMGRDPDLEQRAEELARENEELLEKEAEELEQENAE
LEGECQGLEARNRELRERAESVEREIQYVKDLLIEVYK
ARSQRTRSA, or encoding a mutant form of dn-ATF5,
MASMTGGQQMGRDPDGEQRAEEGARENEEGGEKE
AEEGEQENAEGEGECQGGEARNREGRERAESVEREIQ
YVKDGGIEVYKARSQRTRSA in which the indicated
(bolded) leucines were replaced with glycines to inactivate
leucine zipper activity. The fragments were subcloned
into the BamH1 and XhoI site of pCMV-3Tag-1A (Agi-
lent Technologies Inc, Santa Clara CA) plasmid for in
frame N-terminal 3XFlag-tagged expression of dn-ATF5
or mutant dn-ATF5. Where indicated, experiments
additional employed pLe-FLAG-GFP-dn-ATF5 as pre-
viously described23.
Lentivirus preparation
Lentivirus were prepared in HEK293 cells by co-
transfecting pLVX expression plasmids along with sec-
ond generation lentiviral packaging plasmids using the
calcium phosphate transfection method as previously
described38. Lentiviral particles were collected, then
concentrated using Lenti-X concentrator (#631231,
Takara), resuspended in PBS, and stored at −80°C.
For lentiviral infection, 0.1 up to 5 × 107 viral particles
were added per cm2 of culture area, directly in the culture
medium. The transduced cells were analyzed by qPCR,
Western blot or flow cytometry after 3–5 days.
Flow cytometry
Cells were dissociated with trypsin, and washed with
cold PBS twice, then resuspended in 1 X binding buffer at
a concentration of 1 × 106 cells/ml. About 100 µl of the
solution (1 × 105 cells) were incubated with 5 µl of FITC
Annexin V and 5 µl PI (#556547, BD, Franklin Lakes NJ)
for 15 min at room temperature in the dark. The cell
suspension was mixed with 400 µl of 1X binding buffer
and analyzed by flow cytometry.
qPCR
Cells were lysed and total RNA was purified using TRI
regent (Molecular Research Center, Cincinnati OH) fol-
lowing the manufacturer’s protocol. 1 µg of mRNA was
used for the synthesis of cDNA using the first-strand
cDNA synthesis kit (Origene). qPCR was performed using
FastStart SYBR Green Master Mix (Roche, Indianapolis
IN) by using the following primer pairs: h-Survivin,
CCACTGAGAACGAGCCAGACTT and GTATTACAG
GCGTAAGCCACCG; h-18S RNA, AGTCCCTGCCCT
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TTGTACACA and GATCCGAGGGCCTCACTAAAC.
The relative mRNAs levels for genes of interest were
normalized to 18 S RNA.
Western immunoblotting
Cells were homogenized in cell lysis buffer (#9803, Cell
Signaling Technology, Danvers MA) with protease inhi-
bitor mixture (#11836170001, Roche). Protein samples
were prepared in X2 loading buffer (#161-0737, BioRad,
Portland ME) with βME following the manufacturer’s
instruction. Protein was loaded and separated by elec-
trophoresis and then transferred onto PVDF membranes
(Bio-Rad). Blots were probed with the following primary
antibodies: rabbit anti-survivin (#2808, Cell Signaling
Technology), anti-FLAG (#8146, Cell Signaling Technol-
ogy), mouse anti-ACTIN (#3700, Cell Signaling Tech-
nology), rabbit anti-USP9X (#5751, Cell Signaling
Technology). All band intensities were determined using
ImageJ and normalized to ACTIN signal.
Immunofluorescence
Cells were fixed for 10min in 4% PFA, washed 3 times
with PBS, and blocked with Superblock (#37515 Thermo
Fisher Scientific, Waltham MA) with 0.3% Triton-X for
30min at room temperature. The following primary
antibodies were used for immunofluorescence: rabbit
anti-FLAG (#14793, Cell Signaling Technology), rabbit
anti-GFP (# PA5-22688, Invitrogen), rabbit anti-survivin
(#2808, Cell Signaling Technology). Hoechst 33328 was
used to stain nuclei. Images were acquired using a Zeiss
epifluorescence microscope equipped with a digital cam-
era and Axiovision software.
Results
Expression of dn-ATF5 depletes nuclear survivin
expression in tumor cells prior to promotion of apoptotic
cell death
We previously reported that expression of dn-ATF5-
encoding plasmids promotes apoptotic death of a wide
range of tumor cell types, but not of non-transformed
cells2,3,24. As an initial approach to assessing the potential
effect of dn-ATF5 on survivin expression, we transfected
PC3 prostate tumor cells with a previously described
construct expressing GFP-FLAG-dn-ATF523 and deter-
mined total survivin levels by western immunoblotting
after 3 days (Fig. 1a). This revealed an approximate 40%
loss of survivin protein expression (not accounting for a
transfection efficiency of 50–70%).
Similar results were achieved by transfecting T98G
glioblastoma cells with 3xFLAG-dn-ATF5 (Supplemen-
tary Fig. 1). We also carried out a parallel transfection
with a mutated form of this construct in which the critical
leucine residues in the leucine zipper were replaced with
glycine residues. We previously found that such
replacements in a dn form of ATF5 compromises its
capacity to promote cell death27. In contrast to the non-
mutated construct, the mutant construct failed to down-
regulate survivin (Supplementary Fig. 1). Taken together,
these findings indicate that dn-ATF5 reduces survivin
expression in tumor cells and that this requires a func-
tional leucine zipper domain.
To further assess effects of dn-ATF5 on survivin
expression and localization at the cellular level, we trans-
fected T98G and LN229 glioblastoma cells with a GFP-
FLAG-dn-ATF5 construct or with a control plasmid
expressing only GFP. One day after transfection, trans-
fected (GFP+) cells were immunostained for survivin
expression and blindly scored for proportions with either
no, cytoplasmic/nuclear (cells with evident survivin
expression in both nuclei and cytoplasm) or nuclear-only
localized survivin (Fig. 1b). In both lines, about 60% of
control cells showed nuclear-only localization, about 25%
cytoplasmic/nuclear staining and about 15% no detectable
survivin staining (Fig. 1c). In contrast, there was an
approximate 3-fold increase in proportion of cells without
detectable survivin expression (to almost 50% of the
population) (Fig. 1c) after transfection with GFP-FLAG-
dn-ATF5. This appeared to come mainly at the expense of
nuclear survivin for which there was a corresponding loss
in proportion of cells with immunostaining in this com-
partment (Fig. 1c). These effects were sustained in that
they were also evident 3–5 days after transfection (Fig. 1d).
As noted above, dn-ATF5 expression triggers extensive
apoptotic death of tumor cells. This raised the question as
to whether survivin depletion might either precede or be a
result of the death process. We therefore monitored the
proportions of cells with apoptotic nuclei at 1–5 days after
transfection. In agreement with prior findings2, this
revealed no increase in apoptosis compared to controls at
24 h after transfection (Fig. 1e), a time when survivin
expression was already diminished. This contrasted with
later times when both loss of survivin and increased
apoptotic death were apparent (Fig. 1f). Thus, survivin
appears to be lost prior to the appearance of apoptotic
nuclei and to be sustained during the death process.
Cell penetrant synthetic CP-dn-ATF5 depletes survivin
protein in multiple tumor cell lines
We previously described a synthetic version CP-dn-
ATF5 that contains a penetratin domain that permits
rapid cellular uptake of the peptide and that promotes
apoptotic death of a wide variety of tumor types in vitro
and in vivo26,27. We therefore next tested whether this
potential therapeutic prototype form of dn-ATF5 would
also affect tumor cell survivin protein levels. CP-dn-
ATF5 has the advantage that it rapidly reaches all cells in
cultures and that the effects on survivin can therefore be
readily quantified. We initially treated T98G, U87 and
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LN229 cells with 50, 100, and 200 µM CP-dn-ATF5 for
24 h and assessed relative survivin levels. These con-
centrations of CP-dn-ATF5 have little effect on cell
survival or numbers at 24 h, and trigger apoptotic death
in a dose-responsive manner beginning at 2 days and
strongly manifest at 3 days of treatment27. The data
reveal a consistent loss of survivin protein within 24 h
with some degree of variability from experiment to
experiment (Fig. 2a, b).
We next applied single doses of 50, 100, and 200 µM
CP-dn-ATF5 to 12 different human tumor cell lines of
various origins (prostate [PC3, DU145], colon [HCT116],
glioblastoma [U251, U87, T98G, LN229, and GBM12],
breast [MDA-MB-231, BT474, MDA-MB-468 and MCF7]
for 1–3 days and then measured the relative levels of
survivin protein. Dose-dependent reductions in survivin
protein were seen in all lines at 24 h and persisted for the
3 days of treatment with a range of responses, reaching
Fig. 1 Transfection with GFP-FLAG-dn-ATF5 depletes survivin protein prior to onset of cell death. a Transfection with GFP-FLAG-dn-ATF5
depletes survivin in PC3 prostate tumor cells. Cells were transfected as described in methods and assessed 3 days later for relative survivin levels
(normalized to ACTIN) by western immunoblotting. Left panel shows representative blot, right panel shows quantification from 3 independent
experiments. b Examples of survivin localization in T98G cells. Transfected cultures were immunostained for survivin and co-stained with Hoechst
33828 to visualize nuclear DNA. Blue/white arrowhead shows a cell without significant survivin expression. Red and blue arrowheads show cells with
both cytoplasmic (red arrowheads) and nuclear (blue arrowheads) staining. Yellow arrowhead shows a cell with nuclear-only staining. Scale bar=
10 µm. c, d Transfection with GFP-FLAG-dn-ATF5 depletes nuclear-only localized survivin and increases the proportion of cells without detectable
survivin expression in T89G and LN229 cultures at 24 h (C) or at 3–5 d (D). Transfected cells (GFP+) were blindly scored for survivin localization using
criteria described in panel b. Data are from three independent experiments, each carried out in triplicate. In each experiment about 200–300 cells
were evaluated. e Transfection with GFP-FLAG-dn-ATF5 does not increase the incidence of apoptosis in cultures of T89G and LN229 cultures at 24 h, a
time when survivin is already depleted. Transfected cells (GFP+) in cultures described in panels c and d were scored for proportion with apoptotic
nuclei. Data are from three independent experiments, each carried out in triplicate. In each experiment about 200–300 cells were evaluated.
f Transfection with GFP-FLAG-dn-ATF5 promotes cell death at 3–5 days. As in e, but at 5 days for T98G and 3 days for LN229 cells.
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survivin depletion of over 90% in some cases (Fig. 2c and
Supplementary Fig. 2).
We also examined the onset time of survivin protein loss
with CP-dn-ATF5 at 100 µM in T98G cultures. There was
no significant effect at 4 h, but reduction of survivin levels
was evident at 8 h and beyond (Fig. 2d). To determine
whether this depletion of survivin might be the result of cell
death, we also assessed cell viability over time and confirmed
no loss of cells at 24 h with death evident only at 48 and 72 h
(Fig. 2e). Taken together, our data indicate that CP-dn-
ATF5 depletes survivin levels in multiple tumor lines and
appears to do so well before the appearance of cell death.
Fig. 2 Treatment with CP-dn-ATF5 causes a dose- and time-dependent depletion of survivin protein in multiple cancer cell lines prior to
loss of cell viability. a, b CP-dn-ATF5 depletes survivin in T98G, U87 and LN229 glioblastoma cell lines at 24 h after treatment. a Representative
western blots. b Data are from three independent experiments. c CP-dn-ATF5 depletes survivin in T98G, U87 and LN229 glioblastoma cell lines at 48
and 72 h after treatment. Normalized survivin to ACTIN ratios are shown for each lane. d Treatment with CP-dn-ATF5 causes a rapid depletion of
survivin protein in T98G cultures. Normalized survivin to ACTIN ratios are shown for each lane. e Cell death caused by CP-dn-ATF5 (100 µM) in T98G
cultures occurs after survivin depletion. Relative numbers of cells per culture were determined at the indicated times. Three replicate cultures were
evaluated at each time point
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CP-dn-ATF5 depletes survivin mRNA in multiple tumor cell
lines
To determine whether CP-dn-ATF5 affects levels of
survivin mRNA as well as protein, we carried out qPCR
on the 12 cell lines listed above after a single dose expo-
sure to 50, 100, or 200 µM peptide for 48 h. In each case,
there was substantial depletion of survivin mRNA, with a
range of responsiveness among the lines (Fig. 3a–d).
Additional analyses of survivin mRNA in multiple lines
showed time and dose-dependent loss of survivin mRNA
at 24 and 72 h of treatment with changes apparent within
24 h (Supplementary Figs. 3 and 4). A time course study of
survivin mRNA levels in T98G cells (Fig. 3e) parallel to
that described above for survivin protein (Fig. 2d) revealed
that survivin transcripts were already substantially
decreased by 4 h of CP-dn-ATF5 exposure. This well
precedes the onset of cell death in such cells and occurs
before depletion of survivin protein (Fig. 2e).
CP-dn-ATF5 depletes virally-expressed exogenous survivin
protein in multiple tumor cell lines
While our results indicate that CP-dn-ATF5 causes
survivin mRNA depletion, the possibility remained that
CP-dn-ATF5 also causes survivin protein loss by pro-
moting its turnover. To assess this, we infected multiple
tumor lines with lentivirus expressing FLAG-tagged sur-
vivin driven by a CMV promoter. Despite expression of
the protein from a heterologous promoter, exposure to
100 µM CP-dn-ATF5 for 3 d caused substantial reduction
in expression of the exogenous survivin protein in all lines
tested (Fig. 4a). This observation suggests that CP-dn-
ATF5 causes depletion of survivin protein at least partly
by mechanisms independent from its effects on survivin
mRNA.
CP-dn-ATF5 destabilizes cellular survivin protein and
promotes survivin loss via proteasomal degradation
We next examined whether, as appears for over-
expressed survivin, CP-dn-ATF5-promoted reduction of
endogenous survivin also involves a non-transcriptional
mechanism. Prior reports indicate that cellular survivin
levels are subject to post-transcriptional regulation by
degradation39,40. To assess whether CP-dn-ATF5 affects
survivin stability, we pretreated T98G cells with or with-
out this peptide for 24 h and then exposed them to the
translational inhibitor cycloheximide for various times
before determining relative survivin protein levels by
western immunoblotting. As shown in Fig. 4b, c, this
revealed that CP-dn-ATF5 significantly accelerates sur-
vivin turnover under conditions when survivin synthesis is
Fig. 3 Treatment with CP-dn-ATF5 causes a dose- and time-dependent depletion of survivin mRNA in multiple cancer cell lines. a–d CP-dn-
ATF5 depletes survivin mRNA in multiple cancer cell lines at 48 h of treatment. Data are from three independent experiments. e CP-dn-ATF5 (100 µM)
causes rapid depletion of survivin mRNA in T98G cells. Values are from one experiment carried out in triplicate
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blocked. These findings thus indicate that survivin
depletion caused by dn-ATF5 likely reflects decreased
survivin protein stability.
To approach the issue of the mechanism by which dn-
ATF5 affects survivin stability, we generated T98G cells
stably over-expressing FLAG-survivin on a heterologous
promoter. To determine whether the post-translational
component of the effect of CP-dn-ATF5 on survivin is
mediated by the proteasome, we exposed the survivin
over-expressing cells to 100 µM CP-dn-ATF5 for 24 h in
presence or absence of the proteasomal inhibitor epox-
omicin (Fig. 5a). Under such circumstances, FLAG-
survivin levels decreased with CP-dn-ATF5 alone by
about 50% compared with untreated controls; with
epoxomicin alone, FLAG-survivin levels rose by about
three-fold and this level was not reduced by CP-dn-ATF5
co-treatment. Taken together, these data thus indicate
that CP-dn-ATF5 decreases survivin stability and support
the idea that enhanced proteasomal turnover contributes
to survivin depletion caused by CP-dn-ATF5.
USP9X depletion contributes to the CP-dn-ATF5-mediated
decrease in survivin stability
We next explored the mechanism by which CP-dn-
ATF5 treatment leads to survivin protein destabilization.
The deubiquitinase USP9X has been shown to deubiqui-
nate survivin and thus potentially to inhibit its proteaso-
mal degradation41. Although USP9X downregulation in
HeLa cells was reported without effect on survivin protein
levels41, similar downregulation of USP9X in SF188 and
Panc-1 cells resulted in survivin protein depletion42,43.
Our past work has shown that CP-dn-ATF5 dramatically
reduces USP9X levels in multiple tumor cell lines
including T98G cells27. We therefore asked whether such
an effect of CP-dn-ATF5 on USP9X in T98G cells could
contribute to the depletion of survivin seen with this
agent. Accordingly, we used a previously described
USP9X-directed siRNA27 to knockdown USP9X and
compared survivin levels with those in cells receiving a
control siRNA. This revealed a significant loss of survivin
protein (Fig. 5b), but not survivin mRNA (Fig. 5c), thus
indicating that the reduction of USP9X caused by CP-dn-
ATF5 treatment likely contributes to survivin protein
depletion.
Is survivin depletion by CP-dn-ATF5 sufficient to account
for the anti-tumor actions of this agent?
Numerous studies have documented that reduction of
survivin levels is sufficient to promote death of various
tumor cell types30–32,34. We confirmed this with an siRNA
targeting survivin in T98G, HCT116, MCF7, and MDA-
MB-468 cells that induced apoptotic death in each case
(Supplementary Fig. 5). However, while direct targeting of
survivin expression has been raised as a potential treat-
ment for a variety of cancers, to this point, no successful
anti-survivin monotherapy has emerged. In this context,
we thus asked whether the capacity of CP-dn-ATF5 to
deplete survivin is necessary for its ability to promote
tumor cell death or whether this agent also has additional
death-promoting activities. To address this, we first over-
expressed FLAG-survivin in T98G tumor cells and then
assessed the capacity of CP-dn-ATF5 to promote their
death. As shown in Fig. 6a, although CP-dn-ATF5
Fig. 4 CP-dn-ATF5 promotes the turnover of survivin protein.
a CP-dn-ATF5 decreases the expression of exogenous FLAG-survivin.
Indicated cell lines were infected with lentivirus expressing FLAG-
survivin and 48 h later were treated with 100 µM CP-dn-ATF5 for 72 h
and then assessed for relative (to ACTIN) FLAG-survivin levels by
western immunoblotting. Normalized survivin to ACTIN ratios are
shown for each lane. b CP-dn-ATF5 accelerates the turnover of
survivin protein in T98G cells. Replicate cultures were treated for 24 h
with or without (Control) 100 µM CP-dn-ATF5 and then exposed to
50 µM cycloheximide for the indicated times in the continued
presence or absence of CP-dn-ATF5 and then assessed for relative
survivin levels by western immunoblotting. c CP-dn-ATF5 accelerates
the turnover of survivin protein in T98G cells. Cultures were treated as
in b and relative survivin expression determined vs ACTIN and
normalized to the zero time value in each independent experiment.
Numbers of independent experiments for various points are as
follows: Control, 1 h, n= 5; 2 h, n= 6; 3 h, n= 5; 4 h, n= 6; 12 h, n= 1;
24 h,= 5. CP-dn-ATF5: 1 h, n= 5; 2 h, n= 6; 3 h, n= 5; 4 h, n= 5; 12 h,
n= 1, 24 h, n= 6. Mean data points were fitted to an
exponential curve
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reduced the expression of the FLAG-survivin as antici-
pated, even under these conditions exogenous survivin
was expressed at far higher levels than the corresponding
endogenous protein. Despite such high survivin over-
expression, it failed to significantly protect T98G cells
from death caused by 3 days of CP-dn-ATF5 treatment as
indicated by morphology (Fig. 6b), percentage of apop-
totic cells as determined by flow analysis (6 C), or cell
numbers (6D). We also observed similar results by flow
analysis of U87 cells and by cell counts of LN229, GBM12,
MDA-MB-231, U251, and DU145 cultures transfected to
over-express survivin (Supplementary Figs. 6, 7). Finally,
to control for the possibility that CP-dn-ATF5 kills sur-
vivin over-expressing tumor cells by a mechanism apart
from its dn-ATF5 activity, we also asked whether survivin
over-expression would rescue cells transfected with the
pLe-GFP-FLAG-dn-ATF5 plasmid. As shown in Fig. 6e,
over-expressed survivin also failed to protect from
plasmid-delivered dn-ATF5. These findings thus support
the conclusion that while CP-dn-ATF5 rapidly depletes
cells of survivin, it has additional actions that can promote
cell death that cannot be rescued by survivin over-
expression.
The inability of survivin over-expression to rescue
tumor cells from the lethal effects of dn-ATF5 exposure
raised the question of whether CP-dn-ATF5 might kill
tumor cells by a non-apoptotic mechanism. Our past
work showed that tumor cell death promoted by trans-
fected dn-ATF5 plasmid is apoptotic in nature and is
blocked by inhibition of caspase activity2. We confirmed
this for CP-dn-ATF5 in the present study in which the
caspase inhibitor zVAD rescued cell numbers and the
occurrence of apoptotic nuclei from the effects of 3 days
of peptide exposure (Supplementary Fig. 8). Past work has
shown that dn-ATF5 expression leads to downregulation
of pro-survival BCL29,27,28. We therefore additionally
assessed whether BCL2 over-expression would protect
T98G cells from 3 days of CP-dn-ATF5 treatment. While
Bcl2 over-expression reduced the presence of apoptotic
nuclei, such protection from CP-dn-ATF5 was only par-
tial (Supplementary Fig. 9). Taken together, these findings
support the idea that dn-ATF5 promotes caspase-
Fig. 5 Proteasomal turnover and USP9X contribute to the depletion of survivin protein by CP-dn-ATF5. a Proteasomal inhibitor epoxomicin
suppresses loss of survivin expression promoted by CP-dn-ATF5. T98G cells stably expressing FLAG-survivin were treated for 100 µM CP-dn-ATF5 for
24 h in presence or absence (Control, CTR) of 10 nM epoxomicin (EPOX) and assessed by western immunoblotting for levels of FLAG-survivin and
ACTIN. Left panel shows representative Western immunoblot. Right panel shows quantification of relative FLAG-survivin levels under each condition.
Data are from three independent experiments. b Knockdown of USP9X reduces levels of survivin protein in T98G cells. Cultures were transfected with
control (CTR) or USP9X siRNA for 72 h and assessed 3 days later for USP9X, survivin and ACTIN protein levels by western immunoblotting (left panel).
Right panel shows relative survivin protein levels for five independent experiments. c USP9X knockdown does not affect survivin mRNA levels in T98G
cells. Cultures were treated as in b and assessed for relative survivin mRNA levels. Data are from 3 independent experiments
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Fig. 6 Survivin over-expression is not sufficient to rescue tumor cells from apoptotic death promoted by dn-ATF5. a CP-dn-ATF5 reduces
expression of over-expressed FLAG-survivin, but to levels far in excess of endogenous survivin. T98G cultures were infected with lentivirus expressing
either pLVX-EF1α-IRES-mCherry (pLV in Figure) or pLVX-EF1α-FLAG-survivin-IRES-mCherry (pLV-survivin in Figure) as indicated and 24 h later treated
with or without 100 µM CP-dn-ATF5 for 3 d and assessed for exogenous and endogenous survivin by western immunoblotting with anti-survivin.
Long exposure shows levels of endogenous survivin. b Survivin over-expression does not rescue the effects of CP-dn-ATF5 on number or appearance
of T98G cells. Cultures were infected with lentiviruses described in panel a as indicated and 24 h later were treated with 100 µM CP-dn-ATF5 for
3 days. Panels show immunofluoresence for mcherry (red) or phase contrast images. Scale bars= 50 µm. c Survivin over-expression does not rescue
T98G cells from apoptotic death promoted by CP-dn-ATF5. Cultures were infected with lentivirus described in panel a and 24 h later were treated
with 100 µM CP-dn-ATF5 for 3 days. Cultures were harvested and analyzed for proportion of apoptotic cells by flow cytometry. Left panel shows the
representative cytometry data and right panel shows quantitative results from three independent experiments, each in triplicate. d Survivin over-
expression does not rescue cell number in T98G cultures treated with CP-dn-ATF5. Cultures were infected with above described lentiviruses and 24 h
later were treated with or without 100 µM CP-dn-ATF5 as indicated for 3 days. Cultures were harvested and analyzed for total cell numbers. Data are
from three independent experiments, each in triplicate. e Survivin over-expression does not rescue promotion of apoptosis by FLAG-GFP-dn-ATF5 in
multiple cancer cell lines. Indicated cell lines were co-transfected as shown with a ratio of pLVX:pLE constructs of 3:1 and transfected (GFP+) cells
were assessed for proportion with apoptotic nuclei 3 days later. Data are from three independent experiments
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dependent apoptotic death of cancer cells and that it does
so by multiple pro-apoptotic actions including down-
regulation of survivin and BCL2. Moreover, owing to the
multiplicity of these actions, replacement of a single pro-
survival protein such as survivin is insufficient to maintain
viability.
Discussion
The present findings establish that dn-ATF5 con-
sistently depletes survivin expression in a wide variety of
human tumor cell lines. This appears to occur by both
decreases in levels of survivin mRNA and enhanced sur-
vivin turnover. These decreases occur rapidly and are
durable. Given survivin’s roles in cancer cell proliferation,
survival, metastasis, and therapeutic resistance30–32,34,35,
dn-ATF5-induced survivin depletion is highly likely to
contribute to dn-ATF5’s anti-tumor actions.
We observed that both plasmid-encoded and a
penetratin-linked synthetic forms of dn-ATF5-promoted
survivin depletion. The plasmid-encoded form has N-
terminal GFP and FLAG tags followed by a linker region
and retains the 25 amino acids C-terminal to the leucine
zipper domain of ATF5. These sequences are not present
in CP-dn-ATF527, thus indicating that they are neither
required for, nor interfere with, the capacity of dn-ATF5
to deplete survivin. Likewise, addition of the N-terminal
penetratin domain in the synthetic form does not appear
to interfere with its capacity to regulate survivin
expression.
It was also conceivable that plasma-encoded and
penetratin-linked dn-ATF5 might be present in different
subcellular compartments that would result in distinct
effects on survivin levels. This did not appear to be the
case, indicating that both forms have similar activities. We
also evaluated a form of 3xFLAG-dn-ATF5 mutated in
the leucine zipper domain. This mutant form failed to
deplete survivin, demonstrating that leucine zipper func-
tion is indispensable for dn-ATF5’s capacity to affect
survivin expression.
One potential issue about the effects of dn-ATF5 on
survivin expression was whether this was a response to,
rather than contributor to, apoptotic death. Our findings
with both transfected and penetratin-linked dn-
ATF5 showed depletion of survivin mRNA and protein
well before onset of cell death, thus supporting a role for
survivin depletion as a primary contributor rather than
responder to cell death triggered by dn-ATF5.
Our findings indicate that dn-ATF5 selectively depletes
nuclear-localized survivin. It has been reported that sur-
vivin turns over more efficiently in nuclei44–46. In this
light, given that dn-ATF5 rapidly diminishes survivin
mRNA levels, loss of nuclear survivin may reflect
decreased survivin synthesis that cannot keep up with the
level of degradation in this compartment. Additionally, or
alternatively, dn-ATF5 may affect survivin movement
between the cytoplasmic and nuclear compartments, so
that nuclear import is reduced or export is increased. In
either case, loss of nuclear localization would suggest that
at least one consequence of survivin depletion by dn-
ATF5 is defective cell cycle progression.
The mechanisms that underlie the depletion of survivin
by dn-ATF5 appear to be complex with both reduction of
mRNA levels and post-translational degradation playing
roles (Fig. 7). It is presently unknown whether survivin is a
direct or indirect transcriptional target of ATF5 or whe-
ther dn-ATF5 might act by binding and sequestering
another partner that influences survivin mRNA or protein
expression. Our findings that dn-ATF5 reduces expres-
sion of survivin protein encoded by plasmids with het-
erologous promoters and that it accelerates turnover of
endogenous survivin establish a role for a post-
translational mechanism in survivin depletion. Prior
work shows that survivin is subject to proteasomal
degradation39,40. Consistent with this, we found that the
proteasomal inhibitor epoxomicin elevated expression of
transfected FLAG-survivin. We also observed that epox-
omicin blocked the depletion of FLAG-survivin by CP-dn-
ATF5, a finding that supports the idea that one
mechanism by which dn-ATF5 reduces survivin is by
promoting its proteasomal destruction. Survivin appears
to be protected from proteasomal degradation by inter-
action with partners such as HSP9047 and by deubiquiti-
nation by enzymes including USP9X42,43. We previously
reported that CP-dn-ATF5 substantially reduces expres-
sion of USP9X in a variety of tumor cell lines27. This
raised the possibility that enhanced survivin turnover by
dn-ATF5 is mediated at least in part by USP9X depletion
(Fig. 7) and in support of this, we found that USP9X
knockdown in T98G cells results in a significant reduction
of survivin protein levels.
Among the issues explored here was whether survivin
depletion fully accounts for the apoptotic activity of dn-
ATF5. The degree of survivin depletion in many cell lines
achieved with dn-ATF5 (in some cases, >90%) was on the
order reached by survivin si- or sh-RNA treatments that
Fig. 7 Proposed role of survivin regulation in the mechanism by which
dn-ATF5 kills tumor cells
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elicit apoptotic tumor cell death. Thus, it appears that the
depletion of survivin caused by dn-ATF5 is likely to be
sufficient to cause death. On the other hand, our experi-
ments indicated that death of tumor cells promoted by
CP-dn-ATF5 was not rescued by survivin over-
expression. This suggests that dn-ATF5 triggers pro-
apoptotic events in addition to survivin depletion that are
sufficient to kill cancer cells. Thus far, additional identi-
fied actions of dn-ATF5 that could contribute to its
apoptotic actions include depletion of MCL1 and
BCL25,10,27,28 (Fig. 7) and it is highly likely that more
remain to be identified. The potential capacity of dn-
ATF5 therapeutics to deplete survivin as well as other
survival-promoting proteins may represent an advantage
over drugs such as siRNAs that target only survivin.
In addition to promoting cancer cell death as mono-
therapies, agents that reduce survivin expression or
activity are reported to sensitize tumor cells to che-
motherapeutics or radiation30–35. Because dn-ATF5
depletes survivin in tumor cells, this suggests that it
may also serve in combination therapies to overcome
therapeutic resistance. This possibility is supported by
reports that dn-ATF5 sensitizes pancreatic cancer cells to
paclitaxel9 and that ATF5 promotes radioresistance of
lung cancer cells11.
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